Sign In
Buy NBRV
$1.42
+0 (+0%)
At Close: Nov 24, 2023
Nabriva Therapeutics plc (NBRV) CEO Theodore Schroeder on Q3 2021 Results - Earnings Call Transcript
08:40pm, Tuesday, 09'th Nov 2021
Nabriva Therapeutics plc (NBRV) CEO Theodore Schroeder on Q3 2021 Results - Earnings Call Transcript
Nabriva Therapeutics to Present at the Jefferies London Healthcare Conference
07:01am, Friday, 05'th Nov 2021
DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inn
Nabriva Therapeutics to Report Third Quarter 2021 Financial Results and Recent Corporate Highlights on November 9, 2021
07:01am, Tuesday, 26'th Oct 2021
DUBLIN, Ireland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective ag
Nabriva Therapeutics to Present Data at CHEST Annual Meeting 2021
04:05pm, Friday, 15'th Oct 2021
DUBLIN, Ireland and FORT WASHINGTON, Pa., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inn
Nabriva Publishes Data Demonstrating the Potent Anti-Inflammatory Properties of XENLETA® (lefamulin)
04:05pm, Monday, 04'th Oct 2021
DUBLIN, Ireland and FORT WASHINGTON, Pa., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inn
Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 01'st Oct 2021
DUBLIN, Ireland, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective ag
Nabriva Therapeutics Appoints Dr. Christine Guico-Pabia, M.D., as Chief Medical Officer
07:01am, Friday, 01'st Oct 2021
DUBLIN, Ireland and FORT WASHINGTON, Pa., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inn
Nabriva Therapeutics to Present Data at IDWeek 2021
07:01am, Friday, 24'th Sep 2021
DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of in
Nabriva Therapeutics, Vizient Inks Xenleta Distribution Pact
10:02am, Thursday, 09'th Sep 2021
Nabriva Therapeutics Plc (NASDAQ: NBRV) entered an agreement with Vizient to offer Xenleta as a contracted product to Vizient's Pharmacy Network Program. Xenleta is indicated for community-acquir
NBRV Stock: Why It Increased Today
09:06am, Thursday, 09'th Sep 2021
The stock price of Nabriva Therapeutics PLC (NASDAQ: NBRV) increased by over 3% pre-market today. This is why it happened.
Nabriva and Vizient Enter into Agreement to Make XENLETA® (lefamulin) Available to Vizient's Pharmacy Network Program
07:01am, Thursday, 09'th Sep 2021
- Expands access to XENLETA for hospitalized patients with Community Acquired Bacterial Pneumonia (CABP) - Expands access to XENLETA for hospitalized patients with Community Acquired Bacterial Pneumon
Lefamulin Receives Approval in Taiwan for Treatment of Community-Acquired Pneumonia
07:01am, Wednesday, 08'th Sep 2021
DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of in
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:01am, Wednesday, 01'st Sep 2021
DUBLIN, Ireland, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective a
Nabriva Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
04:05pm, Tuesday, 31'st Aug 2021
DUBLIN, Ireland and FORT WASHINGTON, Pa., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inn
Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q2 2021 Results - Earnings Call Transcript
04:43pm, Friday, 06'th Aug 2021
Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q2 2021 Results - Earnings Call Transcript
